Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the antithrombotic effects of clopidogrel and acetylsalicylic acid in rats

被引：0
|
作者：
Perzborn, E. [1 ]
Fischer, E. [1 ]
Lange, U. [1 ]
机构：
[1] Bayer HealthCare, Cardiovasc Res, Wuppertal, Germany
来源：
EUROPEAN HEART JOURNAL | 2007年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [21] The direct factor Xa inhibitor rivaroxaban
    Verma, Abhishek K.
    Brighton, Timothy A.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (07) : 379 - 383
  • [22] Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
    Hillarp, A.
    Baghaei, F.
    Blixter, I. Fagerberg
    Gustafsson, K. M.
    Stigendal, L.
    Sten-Linder, M.
    Strandberg, K.
    Lindahl, T. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) : 133 - 139
  • [23] The therapeutic potential of enhanced thrombolysis with rivaroxaban, an oral, direct factor Xa inhibitor, in patients with thrombosis
    Varin, R.
    Mirshahi, S.
    Mirshahi, P.
    Li, H.
    Kierzek, G.
    Vigneau, J. F.
    Perzborn, E.
    Mirshahi, M.
    Soria, C.
    Soria, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 33 - 33
  • [24] Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
    Kwong, Louis M.
    ORTHOPEDICS, 2012, 35 (11) : 919 - 919
  • [25] A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban
    Hosny, Noha M.
    MICROCHEMICAL JOURNAL, 2020, 159
  • [26] Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
    Kwong, Louis M.
    ORTHOPEDICS, 2012, 35 (06) : E932 - E938
  • [27] Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor
    Perzborn, E.
    Hardwardt, M.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 380
  • [28] Rivaroxaban: A New Oral Factor Xa Inhibitor
    Perzborn, Elisabeth
    Roehrig, Susanne
    Straub, Alexander
    Kubitza, Dagmar
    Mueck, Wolfgang
    Laux, Volker
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (03) : 376 - U24
  • [29] Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Halabi, Atef
    Maatouk, Haidar
    Klause, Norbert
    Lufft, Volkmar
    Wand, Dominic D.
    Philipp, Thomas
    Bruck, Heike
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) : 703 - 712
  • [30] Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
    Samama, Meyer Michel
    Martinoli, Jean-Luc
    LeFlem, Lena
    Guinet, Celine
    Plu-Bureau, Genevieve
    Depasse, Francois
    Perzborn, Elisabeth
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) : 815 - 825
12345